Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Borrello, US

Ivan Borrello, Baltimore, MD US

Patent application numberDescriptionPublished
20080260758UNIVERSAL GM-CSF EXPRESSING BYSTANDER HUMAN K562 CELL LINE - The present invention provides a universal immunomodulatory cytokine-expressing bystander cell line, a composition comprising such a cell line and a cancer antigen, a method of making such a cell line, and a method of using such a composition.10-23-2008

Ivan M. Borrello, Baltimore, MD US

Patent application numberDescriptionPublished
20090074796Pde5 inhibitor compositions and methods for immunotherapy - The invention features methods and compositions featuring a PDE5 inhibitor for treating or preventing immunological-mediated disease in a subject.03-19-2009
20100272760CANCER IMMUNOTHERAPY WITH A VIRAL ANTIGEN-DEFINED, IMMUNOMODULATOR-SECRETING CELL VACCINE - A human cell line, which lacks major histocompatibility class I (MHC-I) antigens and major histocompatibility class II (MHC-II) antigens and which has been modified to comprise and express (i) a nucleotide sequence encoding an immunomodulator and (ii) a nucleotide sequence encoding a viral antigen, and a method of inducing or stimulating an immune response in a human to a viral-associated disease or cancer comprising administering to the human (i) the aforementioned human cell line in an amount sufficient to induce or stimulate an immune response to the viral associated disease or cancer, (ii) a human cell line, which lacks MHC-I and MHC-11 antigens and which has been modified to comprise and express a nucleotide sequence encoding an immunomodulator, and a human cell line, which lacks MHC-I and MHC-II antigens and which has been modified to comprise and express a nucleotide sequence encoding an antigen of EBV, simultaneously or sequentially in either order, by the same or different routes, in amounts sufficient to induce or stimulate an immune response to the viral-associated disease or cancer, or (iii) an immunomodulator and a human cell line, which lacks MHC-I and MHC-II antigens and which has been modified to comprise and express a nucleotide sequence encoding an antigen of EBV, simultaneously or sequentially in either order, by the same or different routes, in amounts sufficient to induce or stimulate an immune response to the viral associated disease or cancer.10-28-2010

Patent applications by Ivan M. Borrello, Baltimore, MD US

Ivan Marques Borrello, Baltimore, MD US

Patent application numberDescriptionPublished
20110223146METHODS FOR PREPARATION AND USE OF MARROW INFILTRATNG LYMPHOCTYES (MILS) - The invention provides compositions comprising activated marrow infiltrating lymphocytes, methods of generating populations of marrow infiltrating lymphocytes, uses of the marrow infiltrating lymphocytes of the invention, and a culture device for use in cell culture, for example for use in generating populations of activated marrow infiltrating lymphocytes. In certain embodiments, the marrow infiltrating lymphocytes can be used as a cancer therapeutic.09-15-2011

Melinda A. Borrello, Pittsford, NY US

Patent application numberDescriptionPublished
20090312263Gene Differentially Expressed in Breast and Bladder Cancer and Encoded Polypeptides - The present invention relates to a novel human gene that is differentially expressed in human carcinoma. More specifically, the present invention relates to methods of treating or preventing a disorder in a subject. The invention further relates to uses of C35 polypeptides in immunogenic compositions or vaccines, to induce antibody or T cell-mediated immunity against target cells, such as tumor cells, that express the C35 gene. The present invention further relates to use of C35 polypeptides in diagnosing a pathological condition or susceptibility to a pathological condition in a subject.12-17-2009

Michael A. Borrello, Carlsbad, CA US

Patent application numberDescriptionPublished
20110126833CLOSED LOOP CONTROL SYSTEM FOR A HIGH FREQUENCY OSCILLATION VENTILATOR - A control system for a high frequency oscillating ventilator (HFOV) includes an oscillator controller and a mean airway pressure (MAP) controller. The HFOV includes a reciprocating piston which is adapted to generate positive and negative pressure waves for delivery to a patient airway. The oscillator controller comprises a pair of closed loop control circuits including an oscillator pressure loop and a centering loop which are collectively adapted to regulate frequency and amplitude of piston reciprocations and centering of the piston. The MAP controller comprises a closed loop control circuit that is adapted for regulating MAP at the patient utilizing feedback in the form of patient circuit pressure. Likewise, the oscillator controller utilizes patient circuit pressure as well as piston displacement feedback in order to regulate movement of the piston.06-02-2011

Mike Borrello, Carlsbad, CA US

Patent application numberDescriptionPublished
20090048535Detecting Cross-contamination in Blood Measurements with a Multilumen Catheter - The present invention comprises methods and apparatuses that can provide accurate measurement of glucose or other analytes from a multilumen catheter in the presence of infusion of substances, including glucose. Examples of “multilumen catheters” include central venous catheters having multiple lumens, midline catheters having multiple lumens, multiple catheters configured or emplaced such that their lumens are in proximity to each other, and, in the case of indwelling analyte sensors, a catheter with a lumen for infusion and an indwelling sensor spaced apart from the infusion lumen. For blood withdrawal, anti-cross contamination controls can prevent the entrainment of blood which might be contaminated with feeding fluids or medications that are administered through other lumens within the catheter and in proximity of the blood sampling port. Cross contamination can occur under various situations, and is known to occur when the patient is connected to a ventilator. The ventilator cyclically raises the intra-thoracic pressure and diminishes blood flow rate in the central veins returning to the heart. The diminished flow can increase the chances for cross-contamination when additional lumens are introducing fluids during a draw sample.02-19-2009
20090048576Managing Cross-contamination in Blood Samples Withdrawn from a Multilumen Catheter - The present invention comprises methods and apparatuses that can provide accurate measurement of glucose or other analytes from a multilumen catheter in the presence of infusion of substances, including glucose. Examples of “multilumen catheters” include central venous catheters having multiple lumens, midline catheters having multiple lumens, multiple catheters configured or emplaced such that their lumens are in proximity to each other, and, in the case of indwelling analyte sensors, a catheter with a lumen for infusion and an indwelling sensor spaced apart from the infusion lumen. For blood withdrawal, anti-cross contamination controls can prevent the entrainment of blood which might be contaminated with feeding fluids or medications that are administered through other lumens within the catheter and in proximity of the blood sampling port. Cross contamination can occur under various situations, and is known to occur when the patient is connected to a ventilator. The ventilator cyclically raises the intra-thoracic pressure and diminishes blood flow rate in the central veins returning to the heart. The diminished flow can increase the chances for cross-contamination when additional lumens are introducing fluids during a draw sample.02-19-2009
20090054753Variable Sampling Interval for Blood Analyte Determinations - The present invention provides methods and apparatuses that can provide measurement of glucose with variable intervals between measurements, allowing more efficient measurement with greater patient safety. A method according to the present invention can comprise measuring the value of an analyte such as glucose at a first time; determining a second time from a patient condition, an environmental condition, or a combination thereof; then measuring the value of the analyte at the second time (where the second time can be expressed as an interval after the first time, an absolute time, or a time indicated when certain patient or environmental conditions, or both, are reached or detected). The second time can be determined, as an example, from a comparison of the analyte value at the first time with a threshold. The interval between the first time and the second time can be related to the difference between the analyte value at the first time and the threshold; e.g., the closer to the threshold, the closer the two measurement times. The invention can be used with automated measurement systems, allowing the system to determine measurement times and automatically make measurements at the determined times, reducing operator interaction and operator error.02-26-2009
20090054754CLINICIAN-CONTROLLED SEMI-AUTOMATED MEDICATION MANAGEMENT - The present invention is directed to methods and apparatuses of medication management based upon active authorization of medication infusion by a clinician that can provide for effective management of an analyte in a patient's blood, reducing the opportunities for human error common with current manual systems while still placing final control of the medication management with the human clinician. For example, a semi-automated glucose management system can measure the glucose level in a patient's blood, recommend infusion parameters to a clinician who can authorize an infusion of glucose or insulin, and infuse the glucose or insulin into the patient.02-26-2009
20090156975Robust System and Methods for Blood Access - Embodiments of the present invention provide robust systems for the removal and subsequent infusion of blood for measurement purposes, and embodiments of the present invention provide methods of operating such systems and providing capabilities such as predicting and avoiding occlusions and/or bubbles, managing occlusions and/or bubbles if they occur, automatic cleaning of the blood access system, and determining and managing the patency of the blood access site. Such operational challenges can occur during any of several phases of operation of a blood access system. Embodiments of the present invention can effectively incorporate a variety of inputs for the identification of trends consistent with present or pending occlusions. An embodiment of the present invention can be aware of the stage of operation, e.g., withdrawal, infusion, or cleaning, and the prior performance of the system. Embodiments of the present invention can have the ability to identify the location of the problem so that effective procedures can be used to resolve the problem.06-18-2009
20100094113HEMODYNAMIC MONITORING DURING AUTOMATED MEASUREMENT OF BLOOD CONSTITUENTS - The present invention provides methods and apparatuses that can provide measurement of analytes such as glucose with a variety of sensors in connection with hemodynamic monitoring. Some embodiments of the present invention enable the use of a single arterial access site for automated blood glucose measurement as well as hemodynamic monitoring. Some embodiments of the present invention can reduce or eliminate nuisance hemodynamic alarms. Some embodiments of the present invention can provide hemodynamic monitoring during an automated analyte measurement process. An example apparatus according to the present invention comprises a blood access system, adapted to remove blood from a body and infuse at least a portion of the blood back into the body. Such an apparatus also comprises an analyte sensor, mounted with or integrated into the blood access system such that the analyte sensor measures the analyte in the blood that has been removed from the body by the blood access system.04-15-2010
20110060199DETERMINATION OF BLOOD PUMP SYSTEM PERFORMANCE AND SAMPLE DILUTION USING A PROPERTY OF FLUID BEING TRANSPORTED - The use of an optical or other measurement in a blood access system enables the determination of a fluid sample appropriate for measurement on a real time basis. This information can be used to control the blood access system and related measurement processes. The determination can be based on, for example, at least one of: optical density, optical scatter, analyte level, temperature, the absolute level of any of the preceding, the stability of any of the preceding, the rate of change of any of the preceding, or the value of any of the preceding relative to another determination. The determination can be made using, for example, at least one of: electrochemical sensor, ion specific electrode, capacitance measurement, impedance measurement, inductance measurement, conductivity measurement, optical measurement, and ultrasound measurement. The present invention relates to determination of the quality of a biological sample in which determination of an analyte concentration is to be made, and various methods and apparatuses related thereto. An evaluation of sample quality can be made by monitoring the temporal changes in the sample properties or characteristics as the biological sample is procured or measured. The methods and apparatuses described herein can be used to evaluate the temporal characteristics of a sample during sample acquisition and/or during determination of the sample analyte or parameter of interest. The sample quality assurance methods and apparatuses described herein can thus be used to ensure that a valid sample has been procured by or presented to an instrument or measurement system for analyte determination, thereby preventing the measurement and reporting of analyte values for a sample that is unstable or otherwise non-representative of the biological system from which the sample was obtained.03-10-2011

Patent applications by Mike Borrello, Carlsbad, CA US